Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway.
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Paris (France). June 1st. 2023. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in
Paris (France). June 1st. 2023. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Follow us LinkedIn
Inotrem 2023 – Legal notices
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS – Follow us LinkedIn
Inotrem 2023 – Legal notices